Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROGRESS: Pre-operative Gefitinib in Resectable EGFR+ NSCLC
NCT02804776Phase 2Completed
- Sponsor
- National Cancer Centre Singapore
- Start
- Jan 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Centre Singapore. Started Jan 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02804776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02804776.